Entering text into the input field will update the search result below

China approves AstraZeneca's Imfinzi for small cell lung cancer

Jul. 19, 2021 7:46 AM ETAstraZeneca PLC (AZN) StockBy: Jonathan Block, SA News Editor

Chinese flag with lot of medical pills isolated
Golden_Brown/iStock via Getty Images

  • China's National Medical Products Administration has approved AstraZeneca's (AZN -0.3%) Imfinzi (durvalumab) as a first-0line treatment for extensive-stage small cell lung cancer.
  • The approval was based on data from the phase 3 CASPIAN trial that

Recommended For You

More Trending News

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC